Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | HMGCR | P04035 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mevastatin SCHEMBL13297669 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRSMN1; SMN2 | |
| Mevastatin SCHEMBL13900408 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRSMN1; SMN2 | |
| Mevastatin SCHEMBL1981408 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRSMN1; SMN2 | |
| Mevastatin SCHEMBL23936978 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRSMN1; SMN2 | |
| Mevastatin SCHEMBL1981409 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRSMN1; SMN2 | |
| Mevastatin SCHEMBL23636208 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRSMN1; SMN2 | |
| Mevastatin SCHEMBL21340588 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRSMN1; SMN2 | |
| Mevastatin SCHEMBL21340571 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRSMN1; SMN2 | |
| Mevastatin SCHEMBL21340628 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRSMN1; SMN2 | |
| Mevastatin SCHEMBL15091134 | 1.00 | CYP3A4 (1.00) | CYP3A4HMGCRLMNATSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120156216-A1 | Methods and Compositions for Treatment of Tumor Metastasis | OH YOUNGMAN (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120156216-A1 | Methods and Compositions for Treatment of Tumor Metastasis | OH YOUNGMAN (US) | 2012-06-21 | — | — | US | disclosed |
| US-20110098314-A1 | STATINS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | ALCON, INC. (CH) | 2011-04-28 | — | — | US | disclosed |
| US-20110098314-A1 | STATINS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | ALCON, INC. (CH) | 2011-04-28 | — | — | US | disclosed |
| US-RE40667-E1 | [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof | WARNER-LAMBERT COMPANY LLC (US) | 2009-03-17 | — | — | US | disclosed |
| US-20090069623-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF RADIATION-INDUCED FIBROSIS | VIRGINIA COMMONWEALTH UNIVERSITY INTELLECTUAL PROPERTY FOUNDATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069623-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF RADIATION-INDUCED FIBROSIS | VIRGINIA COMMONWEALTH UNIVERSITY INTELLECTUAL PROPERTY FOUNDATION (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2005105069-A1 | STATINS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | ALCON, INC. (CH) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069623-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF RADIATION-INDUCED FIBROSIS | FN1, HDGF, RHOA | CYP3A4 4878/4885HMGCR 1361/4885LMNA 293/4885 |
| US-20120156216-A1 | Methods and Compositions for Treatment of Tumor Metastasis | RHOA, HMGCR, HGF | CYP3A4 4113/4885HMGCR 2/4885LMNA 1059/4885 |
| US-20110098314-A1 | STATINS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | HMGCR, HMGB2, GRHPR | CYP3A4 1360/4885HMGCR 1/4885LMNA 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.